Pharma Site Quality Scoring for Predictive Audit Readiness
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pharmaceutical manufacturing sites face challenges in ensuring data integrity compliance and regulatory readiness due to complex and diverse global regulatory standards, leading to undetected quality lapses and resource-intensive, subjective, and retrospective monitoring methods that lack predictive value.
Innovation Solution
A structured, Excel-based analytical framework integrating CALCULUS™, PREDICT™, and SENSOR™ components to quantify compliance and quality health, using weighted scoring to evaluate 11 critical indicators and 132 parameters across GMP systems, providing a unified site health score and predictive audit readiness assessment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional monitoring methods (internal audits, metric dashboards, manual reviews) are used, then compliance assessment is performed, but the methods are isolated, subjective, and retrospective, introducing variability and limiting predictive value
Solution Approach 1:
The compliance assessment is segmented into multiple dimensions including data integrity compliance, audit readiness, and overall operational performance. Each dimension is measured separately using specific indicators (e.g., DI-1 through DI-10 for data integrity, AR-1 through AR-5 for audit readiness), allowing for precise measurement of each aspect while maintaining objectivity through structured evaluation criteria.
Solution Approach 2:
The system performs preliminary assessments continuously to predict future compliance status and audit outcomes. By measuring current state across multiple indicators and applying predictive modeling, the system forecasts potential compliance failures and audit results before they occur, enabling proactive remediation rather than retrospective analysis.
2Adaptability or versatility
If diverse global regulatory standards are applied, then comprehensive compliance coverage is achieved, but alignment complexity and resource requirements increase
Solution Approach 1:
The assessment system is designed with universal indicators that can evaluate compliance across multiple regulatory frameworks simultaneously. The same set of indicators (data integrity, audit readiness, operational performance) applies to different regulatory standards, allowing the system to function universally across diverse regulatory environments without requiring separate assessment systems for each standard.
Solution Approach 2:
The system adapts to different regulatory standards by adjusting the weightings and thresholds of existing indicators rather than creating entirely new assessment frameworks. This allows the same structural system to accommodate varying regulatory requirements through parameter modification, reducing complexity while maintaining comprehensive coverage.
3Quantity of substance
If comprehensive quality metrics are tracked, then overall quality health is monitored, but the metrics remain isolated and do not provide a comprehensive view of site health or regulatory readiness
Solution Approach 1:
The system merges multiple isolated quality metrics into an integrated assessment framework. Data integrity indicators, audit readiness indicators, and operational performance indicators are combined and weighted to produce unified scores that provide a comprehensive view of site health. The integration eliminates information loss by showing how different metrics interrelate and contribute to overall compliance status.
Data Source
AI summary
The present invention relates to a method for quantitatively evaluating the quality health of pharmaceutical manufacturing sites; specifically, the invention pertains to a method that measures audit readiness, data integrity compliance, and overall operational performance of the pharmaceutical manufacturing sites.